MX2021016160A - Anticuerpo dirigido contra el fragmento amino-terminal de la apoe de 12 kda. - Google Patents
Anticuerpo dirigido contra el fragmento amino-terminal de la apoe de 12 kda.Info
- Publication number
- MX2021016160A MX2021016160A MX2021016160A MX2021016160A MX2021016160A MX 2021016160 A MX2021016160 A MX 2021016160A MX 2021016160 A MX2021016160 A MX 2021016160A MX 2021016160 A MX2021016160 A MX 2021016160A MX 2021016160 A MX2021016160 A MX 2021016160A
- Authority
- MX
- Mexico
- Prior art keywords
- terminal fragment
- kda
- directed against
- antibody directed
- apoe
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/775—Apolipopeptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19183405.0A EP3757125A1 (en) | 2019-06-28 | 2019-06-28 | Antibody directed against the apoe amino-terminal fragment of 12 kda |
| PCT/EP2020/067890 WO2020260491A2 (en) | 2019-06-28 | 2020-06-25 | New antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021016160A true MX2021016160A (es) | 2022-04-06 |
Family
ID=67225987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021016160A MX2021016160A (es) | 2019-06-28 | 2020-06-25 | Anticuerpo dirigido contra el fragmento amino-terminal de la apoe de 12 kda. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220242939A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3757125A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022537736A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220029653A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114008074A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020304855A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021025956A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3140999A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL289271A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021016160A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020260491A2 (cg-RX-API-DMAC7.html) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5168045A (en) * | 1989-08-18 | 1992-12-01 | The Scripps Research Institute | Diagnostic systems and methods using polypeptide analogs of apolipoprotein e |
| CA2690434C (en) * | 2007-06-12 | 2018-05-22 | Ac Immune S.A. | Monoclonal anti beta amyloid antibody |
| JP2009092550A (ja) * | 2007-10-10 | 2009-04-30 | Japan Health Science Foundation | うつ病またはうつ状態の同定方法 |
| JP5812418B2 (ja) * | 2009-04-17 | 2015-11-11 | イムナス・ファーマ株式会社 | Aβオリゴマーに特異的に結合する抗体およびその利用 |
| WO2011084714A2 (en) * | 2009-12-17 | 2011-07-14 | Biogen Idec Ma Inc. | STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF |
| US20170218058A1 (en) * | 2016-01-28 | 2017-08-03 | Alector, LLC | Anti-apoe4 antigen-binding proteins and methods of use thereof |
| WO2017189963A1 (en) * | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| KR102607101B1 (ko) * | 2017-01-26 | 2023-11-29 | 제트엘아이피 홀딩 리미티드 | Cd47 항원 결합 유닛 및 그것의 사용 |
-
2019
- 2019-06-28 EP EP19183405.0A patent/EP3757125A1/en not_active Withdrawn
-
2020
- 2020-06-25 EP EP20734930.9A patent/EP3990486A2/en not_active Withdrawn
- 2020-06-25 KR KR1020227000512A patent/KR20220029653A/ko not_active Ceased
- 2020-06-25 CA CA3140999A patent/CA3140999A1/en active Pending
- 2020-06-25 US US17/617,469 patent/US20220242939A1/en not_active Abandoned
- 2020-06-25 MX MX2021016160A patent/MX2021016160A/es unknown
- 2020-06-25 CN CN202080045874.2A patent/CN114008074A/zh active Pending
- 2020-06-25 JP JP2021575056A patent/JP2022537736A/ja active Pending
- 2020-06-25 BR BR112021025956A patent/BR112021025956A2/pt unknown
- 2020-06-25 AU AU2020304855A patent/AU2020304855A1/en not_active Abandoned
- 2020-06-25 WO PCT/EP2020/067890 patent/WO2020260491A2/en not_active Ceased
-
2021
- 2021-12-22 IL IL289271A patent/IL289271A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3140999A1 (en) | 2020-12-30 |
| WO2020260491A3 (en) | 2021-03-04 |
| JP2022537736A (ja) | 2022-08-29 |
| EP3757125A1 (en) | 2020-12-30 |
| CN114008074A (zh) | 2022-02-01 |
| US20220242939A1 (en) | 2022-08-04 |
| KR20220029653A (ko) | 2022-03-08 |
| AU2020304855A1 (en) | 2021-12-23 |
| BR112021025956A2 (pt) | 2022-02-08 |
| WO2020260491A2 (en) | 2020-12-30 |
| EP3990486A2 (en) | 2022-05-04 |
| IL289271A (en) | 2022-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA519402358B1 (ar) | Ccr7 مترافقات عقار جسم مضاد لـ | |
| JOP20210297A1 (ar) | مواد وطرق لحث المناعة التي تساهم فيها الخلايا التائية | |
| IN2012DN02368A (cg-RX-API-DMAC7.html) | ||
| MY187263A (en) | Il-17 reception a antigen binding proteins | |
| PE20071055A1 (es) | Anticuerpos anti mn | |
| MX2009010120A (es) | Proteinas de union, incluyendo anticuerpos, derivados de anticuerpo y fragmentos de anticuerpo, que se unen especificamente cd154 y sus usos. | |
| WO2020146902A3 (en) | Anti-variable muc1* antibodies and uses thereof | |
| TW200510459A (en) | RG1 antibodies and uses thereof | |
| UA107330C2 (uk) | Туберкульозний білок rv3616c та його застосування | |
| MX2010004660A (es) | NUEVOS ANTICUERPOS ESPECIFICOS DE LOS PEPTIDOS ß-AMILOIDES Y SUS USOS COMO AGENTES DE DIAGNOSTICO Y DROGAS. | |
| NZ753324A (en) | Bivalent antibodies masked by coiled coils | |
| EP4527458A3 (en) | Dpp3 binder directed to and binding to specific dpp3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress | |
| CY1115927T1 (el) | Αντισωματα εναντιον της κολοβωμενης παραλλαγης ctf-611 του her2 | |
| MX2025002470A (es) | Combinaciones de anticuerpos anti-c5 y usos de las mismas | |
| EA202091350A1 (ru) | Связывающие молекулы, специфично связывающиеся с тау-белком | |
| PH12013500714A1 (en) | Anticancer fusion protein | |
| EA201992281A1 (ru) | Связывающие молекулы, специфично связывающиеся с тау-белком | |
| PH12022551828A1 (en) | Multispecific antibodies, compositions comprising the same, and vectors and uses thereof | |
| ZA202110285B (en) | Antibodies and methods of use | |
| PH12020552222A1 (en) | Immunodominant proteins and fragments in multiple sclerosis | |
| MX2023002850A (es) | Fragmento de anticuerpo contra proteina activadora de fibroblastos (fap). | |
| MX2025003153A (es) | Anticuerpos anti-ccr8 | |
| WO2019246176A8 (en) | Anti-factor xii/xiia antibodies and uses thereof | |
| EP4269433A3 (en) | Tgf-beta-rii binding proteins | |
| WO2016041553A3 (de) | Monoklonaler antikörper gegen humanes tau-protein |